Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: CEDAX

« Back to Dashboard

Cedax is a drug marketed by Pernix Therap and is included in two NDAs. It is available from three suppliers. There is one patent protecting this drug.

The generic ingredient in CEDAX is ceftibuten dihydrate. Three suppliers are listed for this compound. Additional details are available on the ceftibuten dihydrate profile page.

Summary for Tradename: CEDAX

Suppliers: see list3

Pharmacology for Tradename: CEDAX

Clinical Trials for: CEDAX

Short-term Antibiotic Therapy for Pyelonephritis in Childhood
Status: Terminated Condition: Pyelonephritis

Patients Response to Early Switch To Oral:Osteomyelitis Study
Status: Not yet recruiting Condition: Osteomyelitis

Multicenter Study Comparing Morbidity and Quality of Life Associated in the Treatment by Surgical Resection and the Conservative Treatment, After Favorable Evolution of Purulent Peritonitis That Originates From Diverticulitis Treated by Mini-invasive Surgery
Status: Recruiting Condition: Peritonitis; Diverticulitis

Esophageal High Resolution Manometry and Dysphagia
Status: Completed Condition: Dysphagia

Controlled Trial of Deep Brain Stimulation in Early Patients With Parkinson's Disease
Status: Active, not recruiting Condition: Parkinson Disease

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Status: Active, not recruiting Condition: Multiple Myeloma

Bioequivalence Study of FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET in Healthy Subjects Under Fasting Conditions
Status: Completed Condition: Healthy

Reirradiation and Erbitux in the HNSCC
Status: Recruiting Condition: Head Neck Cancer Squamous Cell.

Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006
Status: Terminated Condition: Alzheimer´s Disease

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease
Status: Completed Condition: Alzheimer's Disease

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pernix Therap
ceftibuten dihydrate
CAPSULE;ORAL050685Dec 20, 1995RXYes<disabled><disabled>
Pernix Therap
ceftibuten dihydrate
FOR SUSPENSION;ORAL050686Dec 20, 1995RXYes5,599,557<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:
Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn